AstraZeneca to Cut 1600 Positions in R&D Reorganization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca to Cut 1600 Positions in R&D Reorganization


ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca announced that it will consolidate its R&D capabilities into three centers located in Cambridge, UK; Gaithersburg, MD in the US; and Mölndal, Sweden.  The move is designed to concentrate R&D near nationally recognized research hubs and to reduce complexity and costs by shrinking the company’s footprint.  The reorganization will lead to the relocation of nearly 2500 positions and an overall estimated reduction in headcount of 1600 positions, according to a company press release. The vast majority of job losses will be in the UK and the US.

AstraZeneca will invest approximately $500 million to establish a new, purpose-built facility in Cambridge that will house the company’s UK-based small molecule and biologics R&D. Cambridge will also become AstraZeneca’s new global corporate headquarters. The consolidation means that R&D will no longer be carried out at the Alderley Park, Cheshire site in the UK. According the release, approximately 1600 positions will relocate from Alderley Park, with the majority going to the new center in Cambridge and the remainder to the company’s nearby Macclesfield manufacturing facility or other AstraZeneca sites overseas. In addition, the majority of corporate and global commercial roles based in London are expected to move to Cambridge, with some going to other AstraZeneca sites. Following the transfer of the company’s headquarters to Cambridge, AstraZeneca’s Paddington office will close by 2016.

Gaithersburg, which is the site of MedImmune’s headquarters and the primary location for AstraZeneca’s biologics activities, will also become home to much of the company’s US-based Global Medicines Development activities for small and large molecules and will accommodate some global marketing and US specialty care commercial functions, according to the release.

In the US, the company expects an overall reduction of approximately 650 positions. Wilmington, DE will remain the company’s North America commercial headquarters. However, with the exit of the Global Medicines Development group and the relocation of global marketing and US specialty care commercial roles, Wilmington will lose approximately 1200 positions. There will be a net increase of approximately 300 positions in Gaithersburg and approximately 170 positions will be moved to other AstraZeneca sites in the US or overseas.

AstraZeneca’s site in Mölndal, near Gothenburg, will continue to be a global center for research and development, with a primary focus on small molecules.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here